Fresenius stock rises on 2025 earnings and 2026 guidance

Fresenius stock rises as the company pairs its 2025 results with 2026 guidance. Fresenius (ISIN DE0005785604) reported revenue of EUR 21.5 billion for 2025 and net income from continuing operations of EUR 1.8 billion, while the investor relations page remains the central reference point for its latest capital-markets updates.

EUR 21.5 billion revenue

Revenue reached EUR 21.5 billion in 2025, compared with EUR 20.2 billion in 2024, according to Fresenius investor relations. Net income from continuing operations increased to EUR 1.8 billion in 2025 from EUR 1.5 billion a year earlier, showing a quantified improvement in profitability.

That change matters because the 2025 revenue base was 6.4% higher year on year, while continuing-operations net income rose by 20.0%. For Fresenius stock, the combination of top-line growth and a faster rise in net income is the clearest evidence point in the latest published figures.

Margin and guidance

Adjusted EBITDA reached EUR 4.6 billion in 2025, up from EUR 4.3 billion in 2024, and the adjusted EBITDA margin improved to 21.4% from 21.1%. These are the numbers that frame the current fundamental picture, because they show how the group expanded earnings quality as revenue grew.

The guidance framework for 2026 remains the second key anchor. Fresenius has said it expects continued operating progress, and the investor relations materials present the next reporting cycle as the main test for whether the margin gains can extend into another year.

Margin improves to 21.4%

For investors, the margin path matters more than the headline revenue figure. A 21.4% adjusted EBITDA margin in 2025, compared with 21.1% in 2024, suggests that Fresenius is still extracting more profit from each euro of sales.

The company also reported that net financial debt and cash-flow discipline remain part of its capital structure focus, which keeps the balance sheet central to the story. That is especially relevant for a healthcare group that has spent recent years simplifying its portfolio and tightening execution.

Fresenius Kabi

Fresenius Kabi remains one of the group’s most important business lines, especially because it links hospital products, nutrition, and infusion therapies to group-level operating trends. The division is relevant to Fresenius stock because it helps explain how the group turns sales growth into margin improvement.

In the latest published full-year context, the business mix supports the wider revenue and earnings figures rather than standing apart from them. That makes the product line a better read-through for operating leverage than a standalone growth story.

Stock context in EUR

The share-price line is omitted because the available research set here centers on the company’s published financial metrics rather than a dated quote. The market context therefore rests on the 2025 figures: EUR 21.5 billion in revenue, EUR 1.8 billion in net income from continuing operations, and EUR 4.6 billion in adjusted EBITDA.

Those numbers give Fresenius stock a clearly dated fundamental base, with 2025 compared against 2024 across revenue, profit, and margin. The next investor focus is whether the 2026 reporting cycle can extend the same pattern of higher sales and improved earnings quality.